Search research articles
Contact Us
Filters
Showing results (11-20 of 17) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 17 results.
British Journal of Cancer
|
December 21, 2018
PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study
Mark D Pegram, Igor Bondarenko, Marina Moreira Costa Zorzetto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2010
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy
Howard A Burris, Hope S Rugo, Svetislava J Vukelja, et al.
Breast Cancer Research and Treatment
|
October 9, 2013
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
Sara A Hurvitz, Florence Dalenc, Mario Campone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 6, 2021
Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer
Bora Lim, David A Potter, Mohamad A Salkeni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 8, 2009
Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
Linda T Vahdat, Brian Pruitt, Carol J Fabian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2012
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer
Edward H Romond, Jong-Hyeon Jeong, Priya Rastogi, et al.
The New England Journal of Medicine
|
October 21, 2005
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
Edward H Romond, Edith A Perez, John Bryant, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 17) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 17 results.
British Journal of Cancer
|
December 21, 2018
PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study
Mark D Pegram, Igor Bondarenko, Marina Moreira Costa Zorzetto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2010
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy
Howard A Burris, Hope S Rugo, Svetislava J Vukelja, et al.
Breast Cancer Research and Treatment
|
October 9, 2013
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
Sara A Hurvitz, Florence Dalenc, Mario Campone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 6, 2021
Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer
Bora Lim, David A Potter, Mohamad A Salkeni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 8, 2009
Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
Linda T Vahdat, Brian Pruitt, Carol J Fabian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2012
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer
Edward H Romond, Jong-Hyeon Jeong, Priya Rastogi, et al.
The New England Journal of Medicine
|
October 21, 2005
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
Edward H Romond, Edith A Perez, John Bryant, et al.
Page
of 2